Genprex, Inc.

GNPX

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001595248

None

No letter

5 of 13 inputs computable; 7 are required, with a score in every sleeve

Scoreboard	
Reliability	0.76 AUC filers with under $12.5M assets; 95% interval 0.65 to 0.86; 63 events, 2020 to 2025
Peer failure rate	0.60% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	under $12.5M assets total assets $10.2M
Standard universe	outside revenue above $1M and assets above $10M
Warnings	dilution, late filer, thin data, degenera... not computable: distress, fortress balance sheet
Inputs computable	5 of 13
Graded from	filings received through Mar 30, 2026 237 days before the rescan; latest periodic filing 10-Q received Nov 13, 2026
Last close	$1.56 2026-11-20; market equity $2.1M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Mar 30, 2026

We are a clinical stage gene therapy company pioneering the development of gene-based therapies for large patient populations with unmet medical needs. Our oncology platform utilizes our systemic, non-viral ONCOPREX® Delivery System which uses lipid-based nanoparticles in a lipoplex form to deliver tumor suppressor gene-expressing plasmids to cancer cells. The product is administered intravenously, where it is taken up by tumor cells that then express tumor suppressor proteins that were deficient in the tumor.

The thirteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 33.5						
Gross profitability	not computable	32.8%				
one or more required annual facts are missing						
Return on invested capital	not computable	9.6%				
one or more required annual facts are missing						

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Accruals ratio	(12.9%)	(6.7%)	33.5	756	2025-12-31
Gross margin stability, five years	not computable	2.8 pts			
five annual gross margins are required; found 0					
Solvency, sleeve percentile 69.4					
Altman Z double-prime	(57.35)	0.31	90.9	705	2025-12-31
Net debt to EBITDA	not computable	1.82x			
one or more required annual facts are missing					
Interest coverage	not computable	(3.61x)			
interest expense must exceed $100,000					
Current ratio	3.84x	2.68x	47.9	781	2025-12-31
Growth and financing, sleeve percentile 94.1					
Revenue growth, three-year compound	not computable	9.6%			
current value must be positive and the base must exceed $100,000					
Free cash flow growth, three-year compound	not computable	11.1%			
current FCF must be positive and base FCF must exceed $100,000					
Reinvestment rate	not computable	33.9%			
one or more required annual facts are missing					
Asset growth, three years	(26.0%)	3.2%	90.5	663	2025-12-31
Net share issuance, one year	1,772.4%	1.6%	97.8	626	2026-03-27

Warnings

4 of 7 checks triggered; none of them enters the letter

Check	Measured
Dilution	split-adjusted year-over-year share growth is 1772.4%
Late filer	found 1 NT 10-K/Q filings in the last eight quarters
Thin data	5 of 13 grade factors are computable; minimum is 7
Degenerate inputs	latest revenue or assets are at or below the $100,000 validity floor

What the price implies

at the 2026-11-20 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(97.7%)	(1.7%)	0
Distance from 52-week high	(98.1%)	(33.0%)	1
EBIT to enterprise value	not computable	0.5%	
Free cash flow yield	(910.5%)	0.6%	1
Book value to price	7.09	0.29	99
Sales to price	0.00	0.38	0
Composite equity issuance, five years	721.3%	13.5%	99
Relative strength against the sector, log excess return	(3.94)	(0.19)	0
Twelve-month failure probability, CHS model	not computable	0.06%	

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	fail

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	$15.3M
Operating cash flow, four quarters	-$15.3M
Months of runway	12.0
Days since last periodic filing	9 (10-Q received Nov 13, 2026)
Median daily dollar volume, 63 sessions	$294,852

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	net income	us-gaap:NetIncomeLoss	-$16.2M	2025-12-31	2026-03-30	10-K	26-010346
2	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$15.3M	2025-12-31	2026-03-30	10-K	26-010346
3	assets	us-gaap:Assets	$10.2M	2025-12-31	2026-03-30	10-K	26-010346
4	assets	us-gaap:Assets	$4.1M	2024-12-31	2026-03-30	10-K	26-010346
5	current assets	us-gaap:AssetsCurrent	$8.4M	2025-12-31	2026-03-30	10-K	26-010346
6	current liabilities	us-gaap:LiabilitiesCurrent	$2.2M	2025-12-31	2026-03-30	10-K	26-010346
7	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$171.0M	2025-12-31	2026-03-30	10-K	26-010346
8	operating income	us-gaap:OperatingIncomeLoss	-$15.5M	2025-12-31	2026-03-30	10-K	26-010346
9	book equity	us-gaap:StockholdersEquity	$8.0M	2025-12-31	2026-03-30	10-K	26-010346
10	liabilities	us-gaap:Liabilities	$2.2M	2025-12-31	2026-03-30	10-K	26-010346
11	operating income	us-gaap:OperatingIncomeLoss	-$12.4M	2018-12-31	2020-03-30	10-K	20-006522
12	interest expense	us-gaap:InterestExpense	$37,982	2018-12-31	2020-03-30	10-K	20-006522
13	revenue	us-gaap:Revenues	$0	2024-12-31	2025-04-01	10-K	25-010311
14	revenue	us-gaap:Revenues	$0	2023-12-31	2025-04-01	10-K	25-010311
15	revenue	us-gaap:Revenues	$0	2022-12-31	2024-04-01	10-K	24-010426
16	revenue	us-gaap:Revenues	$0	2021-12-31	2023-03-31	10-K	23-008847
17	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$17.6M	2022-12-31	2024-04-01	10-K	24-010426
18	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$0	2022-12-31	2023-03-31	10-K	23-008847
19	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$14.3M	2021-12-31	2023-03-31	10-K	23-008847
20	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$31,700	2021-12-31	2023-03-31	10-K	23-008847
21	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$13.9M	2020-12-31	2022-03-30	10-K	22-007680
22	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$17,564	2020-12-31	2022-03-30	10-K	22-007680
23	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$6.9M	2019-12-31	2021-03-26	10-K	21-007317
24	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$33,370	2019-12-31	2021-03-26	10-K	21-007317
25	assets	us-gaap:Assets	$10.7M	2023-12-31	2025-04-01	10-K	25-010311
26	assets	us-gaap:Assets	$25.1M	2022-12-31	2024-04-01	10-K	24-010426
27	shares outstanding	dei:EntityCommonStockSharesOutstanding	9,044,856	2026-03-27	2026-03-30	10-K	26-010346
28	shares outstanding	dei:EntityCommonStockSharesOutstanding	24,152,848	2025-03-28	2025-04-01	10-K	25-010311

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.